Related references
Note: Only part of the references are listed.
Meeting Abstract
Oncology
ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HR-PC) and bone metastases
N. D. James et al.
EJC SUPPLEMENTS (2007)
Article
Oncology
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Share Paper
